科尔奇辛在患有大动脉狭窄症的患者中进行过导管大动脉置换:双盲随机试验
Christoph Ryffel1,2, Jonas Lanz1, Nicole Guntli1
1Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Nature communications
|July 14, 2025
概括
科尔奇辛可以减少通过导管的大动脉置换 (TAVR) 后的心律失常和小叶血栓形成. 然而,该试验因科尔奇辛组中风风险增加而提前停止,因此需要进一步调查.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症是一个潜在的风险因素为心律失常后透气管大动脉置换 (TAVR).
- 作为一种抗炎药物,科尔奇辛还没有被广泛地研究这个适用症.
研究的目的:
- 为了研究胆固醇在减少TAVR后新发动的心房动或心房导电障碍方面的疗效.
- 评估菌素对亚临床传单血栓形成的影响.
主要方法:
- 一个单中心,双盲,安慰剂控制,随机化试验,涉及120名接受TAVR的患者.
- 患者被随机分配,接受胆固醇或安慰剂.
- 该试验因临时分析显示,素组中风率较高,因此提前停止了试验.
主要成果:
- 主要终点 (心律失常) 发生在10%的黄素组,而安慰剂组的25% (p=0.031).
- 亚临床小册子血栓发生在27%的胆固醇组,相比之下,在安慰剂组的54% (p=0.007).
- 胆固醇组中发生了5次中风,而安慰剂组中没有中风 (p=0.022),导致试验终止.
结论:
- 在TAVR之后,外科治疗可减少心律失常和亚临床小册子血栓形成.
- 观察到中风事件的增加需要谨慎和进一步的研究,在广泛采用之前.
- 需要进行确认性试验来验证这些发现,并评估TAVR患者中胆固醇的整体风险益处概况.
更多相关视频
相关概念视频
Aortic Regurgitation III: Medical Management
47
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
47
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257
Mitral Stenosis III: Medical Management
27
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
27
Atherosclerosis III: Management
40
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
40
Peripheral Artery Disease III: Interprofessional Care
30
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
30


